TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02420652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given metformin hydrochloride placebo PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given aspirin placebo PO
Study: NCT01284556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Description: tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: tablet
Study: NCT04512885

Intervention type: OTHER
Intervention: Survey
Description: Survey via questionnaire

Intervention type: OTHER
Intervention: Survey
Description: Survey via questionnaire
Study: NCT02660580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB11022
Description: Participants received MSB11022 drug subcutaneously MSB11022 (Core Treatment Period), MSB11022 (Extended Treatment Period) and EU-Humira/MSB11022 arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB11022
Description: Participants received MSB11022 drug subcutaneously MSB11022 (Core Treatment Period), MSB11022 (Extended Treatment Period) and EU-Humira/MSB11022 arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB11022
Description: Participants received MSB11022 drug subcutaneously MSB11022 (Core Treatment Period), MSB11022 (Extended Treatment Period) and EU-Humira/MSB11022 arm.
Study: NCT03195842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recordable card
Study: NCT01933815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI 287
Description: TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
Study: NCT00655798

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Yogurt containing Bifidobacterium animalis ssp.
Description: Yogurt containing the probiotic Bifidobacterium animalis ssp.
Study: NCT03383133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SULT Allosteric Inhibition
Description: A single, therapeutic dose of acetaminophen (APAP, 1.0 g)) or dehydroepiandrosterone (DHEA, 75 mg) is taken orally (with 375 ml of water) either alone or simultaneously with a single, oral, therapeutic dose of mefenamic acid (MEF, 0.75 g). In total, 5 experiments will be performed. Each experiment is performed in duplicate. Compounds are taken prior to eating breakfast. One hour later, the patient has a light breakfast and eats normally thereafter. Urine samples are collected at 15', 30', 1 h, 2h, 3h, 4h, 5 h, 6h, 7h, 8h, 9h, 10h, 11h, and 12h intervals following dosing. The samples are weighed. A 10 ml aliquot is taken from each time point and the aliquots are stored at -20 °C. Samples (0.5 ml) are then transferred to NMR tubes spectra are taken to assess drug metabolites in urine.
Study: NCT02618187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER-287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER-287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER-287

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pre-Treat
Study: NCT01822353

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement
Description: Milk, egg or nut oral immunotherapy

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement
Description: Milk, egg or nut oral immunotherapy
Study: NCT02618187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Pre-Treat
Study: NCT02223585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal-based protein diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegan-based protein diet
Study: NCT05025137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flexi-Bar Exercise
Description: In the experimental group, the Flexi-Bar was adopted as the tool for active vibration exercises. Featuring light weight and ease of operation, it weighs only 460 grams and has a vibration frequency of 4-5 Hz. With diversified functions, the Flexi-Bar can improve posture, burn fat, strengthen connective tissue, enhance body shape, and increase muscle strength.~The 12-week Flexi-Bar exercise course in this study was created by two assistant professors specializing in rehabilitation (one with an occupational therapy certificate and the other with a physical therapy certificate). The course, composed of one 60-minute class per week for a total of 12 weeks, progressed gradually from basic activities (e.g., standing with both feet) to advanced activities (e.g., standing with one foot).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-Component exercise
Description: Alternatively, in the control group, the Multi-Component exercise was adopted, which included aerobic, resistance, flexibility, and balance exercises. The course was composed of one 60-minute class per week for a total of 12 weeks. The design was based on the ACSM's recommendations for the multiple-component exercise of the elderly (Chodzko-Zajko et al., 2009) and videos of the National Health Exercises for the Elderly formulated by the Ministry of Health and Welfare (Ministry of Health and Welfare, 2017). The course was created and led by a physical therapist to gradually progress from sitting postures to standing and walking postures. Additionally, the intensity of the exercises was adjusted according to the participants' physical conditions; fitness equipment was introduced when appropriate.
Study: NCT01602575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based Stress Reduction Training (MBSR)
Description: 8 (2 hr) classes weekly of MBSR and required homework of MBSR practice approximately 30 minutes per day.
Study: NCT03162159

Intervention type: OTHER
Intervention: Collection of growth and bone maturation data

Intervention type: OTHER
Intervention: Collection of growth and bone maturation data
Study: NCT01310998

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity exercise
Description: 4x4 intervals
Study: NCT01822353

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement
Description: Milk, egg or nut oral immunotherapy
Study: NCT02833662

Intervention type: OTHER
Group type: OTHER
Intervention: Measure of ODI and heart rhythm
Description: Record nocturnal respiratory and cardiac parameters before and after surgery.
Study: NCT04685733

Intervention type: DEVICE
Intervention: Non-invasive hemodynamic measurements
Description: Non-invasive hemodynamic measurements

Intervention type: DEVICE
Intervention: Non-invasive hemodynamic measurements
Description: Non-invasive hemodynamic measurements
Study: NCT02618187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Pre-Treat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Pre-Treat
Study: NCT02539407

Intervention type: OTHER
Intervention: Pharmacokinetics
Study: NCT00160615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: * Pharmaceutical form: Film-coating tablets~* Concentration: 250 mg/ 500 mg~* Route of administration: oral use
Study: NCT01936974

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Patient to receive gemzar

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patient to receive gemzar
Study: NCT01310998

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity exercise
Description: 4x4 intervals

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity exercise
Description: 4x4 intervals
Study: NCT01728181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: The phase I study will test two dose levels of tivozanib (dose level 1: 1.0 mg and dose level 2: 1.5 mg) given daily for 3 consecutive weeks followed by one week break. Based on the phase I results, the dose of tivozanib will be chosen for the phase II study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tivozanib
Description: The phase I study will test two dose levels of tivozanib (dose level 1: 1.0 mg and dose level 2: 1.5 mg) given daily for 3 consecutive weeks followed by one week break. Based on the phase I results, the dose of tivozanib will be chosen for the phase II study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg/day for 28 day cycle. No rest period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: 150 mg/day for 28 day cycle. No rest period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erlotinib
Description: 150 mg/day for 28 day cycle. No rest period.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care treatment
Description: This treatment will be determined by the study doctor and is considered standard of care.
Study: NCT02191059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study: NCT01923545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-G-CSF
Description: Vial, 3.6mg/day or 6mg/day, single dosing per cycle, for 1 cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-G-CSF
Description: Vial, 3.6mg/day or 6mg/day, single dosing per cycle, for 1 cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Vial, 100ug/m2/day, multiple dosing per cycle(daily administration, up to 10 days), for 1 cycle
Study: NCT03168763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Participants shown Video 1A or 1B, then shown Video 2A or 2B.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Participants shown Video 1A or 1B, then shown Video 2A or 2B.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Participants shown Video 1A or 1B, then shown Video 2A or 2B.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Participants shown Video 1A or 1B, then shown Video 2A or 2B.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed at baseline, after each video viewing, and at completion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed at baseline, after each video viewing, and at completion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed at baseline, after each video viewing, and at completion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed at baseline, after each video viewing, and at completion.
Study: NCT02781883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1001 in combination with Ventoclax plus decitabine
Description: BP1001 in combination with Ventoclax plus decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1001 in combination with Ventoclax plus decitabine
Description: BP1001 in combination with Ventoclax plus decitabine
Study: NCT01936974

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Patient to receive avastin
Study: NCT02781883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1001 plus decitabine
Description: BP1001 plus decitabine in ventoclax intolerant or resistant subjects
Study: NCT05288686

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sentinel lymph node biopsy procedure
Description: Patient received respective tracer injection and sentinel lymph node biopsy was performed in the operation theatre with the corresponding device.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sentinel lymph node biopsy procedure
Description: Patient received respective tracer injection and sentinel lymph node biopsy was performed in the operation theatre with the corresponding device.
Study: NCT00754455

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza VLP Vaccine (recombinant)
Description: Single injection Day 0; 0.5mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza VLP Vaccine (recombinant)
Description: Single injection Day 0; 0.5mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza VLP Vaccine (recombinant)
Description: Single injection Day 0; 0.5mL

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo as a single injection of 0.5 mL.
Study: NCT02417948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written Educational Brochure
Description: Receive brochure with skin cancer education and preventative information

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written Educational Brochure
Description: Receive brochure with skin cancer education and preventative information

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online educational video
Description: Watch 30-minute online tutorial video about skin cancer, preventive behaviors, and skin self-examinations
Study: NCT05371171

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin graft
Description: In the experimental group, the operative plan was to consider taking a 15% larger amount than necessary and replace over-harvested skin back onto the donor site in an island manner. Any remaining skin graft was returned to the donor site and a polyurethane dressing \[Alleyvn, Smith, \& Nephew\] was placed on the regrafted skin for fixation

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: no skin graft
Description: In the experimental group, the operative plan was to consider taking a 15% larger amount than necessary and replace over-harvested skin back onto the donor site in an island manner. Any remaining skin graft was returned to the donor site and a polyurethane dressing \[Alleyvn, Smith, \& Nephew\] was placed on the regrafted skin for fixation
Study: NCT04975529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game on Philly: Engaging Underserved Middle School Youth in Out-of- School Time Sports and Nutrition Education
Description: Two-group quasi experimental intervention with schools assigned to intervention or comparison.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game on Philly: Engaging Underserved Middle School Youth in Out-of- School Time Sports and Nutrition Education
Description: Two-group quasi experimental intervention with schools assigned to intervention or comparison.
Study: NCT02599805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Natrox™ Oxygen Delivery System (ODS)
Description: Natrox™ ODS will be applied to the subject's diabetic ulcer and attached to the active Natrox™ Oxygen Generator using the tubing provided or regular dressing will be used. The Natrox™ oxygen delivery system (ODS) is a device designed to overcome a number of problems associated with previous methods of oxygen therapy by delivering continuous oxygen to the ulcer bed through a dressing.
Study: NCT02481427

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unicondylar Knee Replacement
Description: UKA involves only the replacement of affected medial compartment. In the study, the operation will be performed through standard medial parapatellar incision with midline skin incision, but the knee joint and fascia will be opened like in standard Oxford minimally invasive incision. The procedure will be performed by using Oxford Microplasty instrumentation and following Microplasty surgical technique (Biomet Orthopedics). Intraoperative local infiltration analgesia is used for postoperative pain management. Drain is not used.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Knee Replacement
Description: TKA is performed through a standard medial parapatellar incision, which provides easy access to the knee joint. Skin incision is done to midline. Intramedullary guide is used for alignment of femoral and tibia saw cuts and component positions. Components will be cemented in position. The patella will not be resurfaced. Intraoperative local infiltration analgesia (LIA) is used for postoperative pain management. Drain is not used.
Study: NCT00188708

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hypoxia measurement
Description: transrectal oxygen measurement
Study: NCT01771185

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Duodenal jejunal bypass plus sleeve gastrectomy
Description: Metabolic Surgery Duodenal jejunal bypass plus sleeve gastrectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best medical treatment (Metformin ; gliclazide)
Description: Metformin 2 g/day; gliclazide 30 mg
Study: NCT03096015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Comprehensive Aphasia Program
Study: NCT01445886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indigo Naturalis Extract in Oil
Description: The participants applied indigo naturalis extract in oil topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol Solution
Description: The participants applied calcipotriol solution topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 24 weeks.
Study: NCT01827358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin calcium
Description: Mupirocin calcium cream 2% applied topically to umbilicus and perianal area every 8 hours for 5 days, for a total of 15 applications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin calcium
Description: Mupirocin calcium ointment 2% will be applied intranasally every 8 hours for 5 days, for a total of 15 applications
Study: NCT04685733

Intervention type: DEVICE
Intervention: Non-invasive hemodynamic measurements
Description: Non-invasive hemodynamic measurements
Study: NCT03403257

Intervention type: OTHER
Intervention: No interventions
Description: No intervention

Intervention type: OTHER
Intervention: No interventions
Description: No intervention
Study: NCT01936974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patient to receive avastin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Patient to receive carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patient to receive cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Patient to receive Oxaliplatin
Study: NCT01466231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Tablets p.o. 10 mg daily until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements.
Study: NCT03562871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IO102
Description: test immunotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IO102
Description: test immunotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab (Keytruda)
Description: anti-PD-1 immunotherapy

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pembrolizumab (Keytruda)
Description: anti-PD-1 immunotherapy
Study: NCT01262001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-3019
Description: Cohort 1 and Cohort 1-EX: 15 mg/kg by infusion every 3 weeks for 45 weeks in the target population (first treatment year and first extended treatment year and every 3 weeks thereafter for three additional extended treatment years).
Study: NCT03562871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab (Keytruda)
Description: anti-PD-1 immunotherapy

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pembrolizumab (Keytruda)
Description: anti-PD-1 immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin (Carboplatin Kabi)
Description: chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin (Carboplatin Kabi)
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed (Pemetrexed Alvogen)
Description: chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed (Pemetrexed Alvogen)
Description: chemotherapy
Study: NCT00384527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: One nitazoxanide 500 mg tablet twice daily plus one vancomycin-placebo capsule four times daily for 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: One vancomycin 125 mg capsule four times daily plus one nitazoxanide-placebo twice daily for 10 days.
Study: NCT00367393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Description: Pimecrolimus cream 1% bid, as needed
Study: NCT01262001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-3019
Description: Cohort 2 and Cohort 2-EX: 30 mg/kg by infusion every 3 weeks for 45 weeks in the target population (first treatment year and first extended treatment year and every 3 weeks thereafter for three additional extended treatment years).
Study: NCT02988206

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Personalized Objects
Description: personalized objects are based on the observation or the reports from family

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: non-personalized Objects
Description: non-personalized objects are based on the suggestion in CRS-R,which are comb and cup

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: non-personalized Objects
Description: non-personalized objects are based on the suggestion in CRS-R,which are comb and cup